Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Hockenhull, Juliet ^a   Greenhalgh, Janette ^a   Dickson, Rumona C ^a   Ricciardi, Mark ^b   Patel, Amisha ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Northwestern Medicine Cardiology ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; ACUTE CORONARY SYNDROME; ADULT; CORONARY RESTENOSIS; DRUG ELUTING STENT; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ADULT; ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 84979862563     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004587.pub3     Document Type: Review

References (237)

1. Linnemeier T. The ACTION Study. (Slide presentation, Cardiovascular Research Foundation [CRF] Drug-Eluting Stent Symposium. Transcatheter Cardiovascular Therapeutics [TCTMD] online database) [accessed 31/10/2002]. http://www.tctmd.com/display/expert/pdf/23073/ACTION.pdf. 2002.
2. Serruys P. Final ACTION results (ActinomycinD) ACTinomycineluting stent improves outcomes by reducing neointimal hyperplasia -ACTION TCT 2002, Washington DC, September 25-28 [accessed 21/01/2003]. TCT (Transcatheter Cardiovascular Therapeutics). 2002, issue 21/01/2003.
3. Serruys P, Ormiston F, Sousa E, Grube E, den Heijer P, Feyter P, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. Journal of the American College of Cardiology 2004;44:1363-7.
4. Serruys PW. Actinomycin eluting stent improves outcomes by reducing neointimal hyperplasia (ACTION). European Society of Cardiology XXIV Annual Meeting. Berlin, August 31-September 4, 2002. Available from: http://www.accitalia.it/congress_centre/meeting_int/detail.asp? acr_trial=action [accessed 31/10/2002]. 2002.
5. Grube E, Mueller R, Lim V, Schmidt T, Gerckens U, Buellesfeld L. Evaluation of a new polymer-coated paclitaxel-eluting stent for treatment of de novo lesions: Six-month clinical and angiographic follow-up results of the APPLAUSE trial. Journal of Invasive Cardiology 2006;18(5):194-8.
6. Heldman A. Six-month results of ASPECT. TCT (Transcatheter Cardiovascular Therapeutics) 2001 Conference (Presented on behalf of Park SJ). Available from: http://www.tctmd.com/meeting-news/one.html?news_item_id=2405 [accessed 31/10/2002]. 2001.
7. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003;107(4):517-20.
8. Liakishev AA. [Clinical trial of paclitaxel-eluting stents. Results of ASPECT]. [Russian]. Kardiologiia 2003;43(6):72.
9. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. New England Journal of Medicine 2003;348(16):1537-45.
10. Leibundgut G, Nietlispach F, Pittl U, Brunner-La Rocca H, Kaiser CA, Pfisterer ME. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents. American Heart Journal 2009;158(2):271-6. 2009;158(2):271-6.
11. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. European heart journal 2009;30(1):16-24.
12. Kaiser C, Brunner-La Rocca H, Buser P, Bonetti P, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real world setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
13. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. New England Journal of Medicine 2010;363(24):2310-9.
14. Moon KT. Outcomes of First-Generation drug-eluting stents in large Coronary Artery repair. American Family Physician 2011;84(10):1175.
15. Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, et al. Drug-eluting or bare-metal stents forlarge coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: Study protocol and design. American Heart Journal 2008;155(4):609-14.
16. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. New England Journal of Medicine 2010;363(24):2310-9.
17. Moon KT. Outcomes of First-Generation drug-eluting stents in large Coronary Artery repair. American Family Physician 2011;84(10):1175.
18. Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, et al. Drug-eluting or bare-metal stents forlarge coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: Study protocol and design. American Heart Journal 2008;155(4):609-14.
19. Kaiser C, Brunner-La Rocca H, Buser P, Bonetti P, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a realworld setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
20. Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, et al. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) -study design and rationale. Journal of Cardiovascular Medicine 2009;10(2):192-9.
21. Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, et al. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial. American Journal of Medicine 2011;124(5):434-43.
22. Raber L, Kelbaek H, Ostoijc M, Baumbach A, Heg D, Tuller D, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308(8):777-87.
23. Raber L, Kelbaek H, Ostoijc M, Baumbach A, Tuller D, von Birgelen C, et al. Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. Eurointervention 2012;7(12):1435-43.
24. Reifart N, Hauptmann KE, Rabe A, Enayat D, Giokoglu K. Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: the CORACTO trial. Eurointervention 2010;6(3):356-60.
25. Costa Jr. JR, Sousa A, Siqueira D, Chamie D, Feres F, Costa R, et al. Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents. EuroIntervention 2012;8(2):225-34.
26. Schampaert E. The Canadian multicenter, randomized, double-blind trial of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (C-SIRIUS): 365 day complete clinical follow up. Circulation 2003;108(17 Suppl. S):3193.
27. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). Journal of the American College of Cardiology 2004;43(6):1110-5.
28. Belkacemi A, Agostoni P, Nathoe H, Shao C, Sangiorgi G, Voskuil M, et al. Results of the drug-eluting balloon in acute STEMI (DEB-AMI) trial: A multicenter randomised comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus DES in primary PCI with 6-month angiographic, intravascular, functional and 12-month clinical outcomes. EuroIntervention 2012;8((Supplement N)):N25.
29. Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao C, Van Belle E, et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. Journal of the American College of Cardiology 2012;59(25):2327-37.
30. Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. Jacc: Cardiovascular Interventions 2012;5(3):313-22.
31. Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomes in diabetic patients with multivessel disease and long lesions: results from the DECODE STUDY. American Journal of Cardiology. 2005; Vol. 96 (7) Supplement 1 [TCT 64]:31-2.
32. Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE STUDY. Catheterization and Cardiovascular Interventions 2008;72:591-600.
33. Kaltoft A, Kelbaek H, Clemmensen P, Helqvist S, Lassen JF, Klovgaard L, et al. Long-term outcome after drug-eluting versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the DEDICATION trial. EuroIntervention 2010;6(supplement H). 2010;6(Supplement H):H132.
34. Kaltoft A, Kelbaek H, Thuesen L, Lassen JF, Clemmensen P, Klovgaard L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. Journal of the American College of Cardiology 2010;56(8):641-5.
35. Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Kløvgaard L, Kaltoft A, et al. Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008;9:1155-62.
36. Knopf W. DELIVER -A U.S. multicenter, randomized, single-blind study of the ACHIEVE™ drug coated coronary stent system in the treatment of patients with de novo native coronary lesions. CRT (Cardiovascular Revascularization Therapies). 2003.
37. Knopf W. DELIVER I: final results & afterthoughts. Drug-eluting stent summit @ Transcatheter Cardiovascular Therapeutics (TCT) Available from: http://www.tctmd.com/display/expert/pdf/79872/knopf-deliverdesstct03.pdf [accessed 2003 07/10/03]. 2003.
38. Knopf W, O'Neill W, Fitzgerald P. A premier presentation of DELIVER trial results at CRT 2003. CRT (Cardiovascular Revascularization Therapies) 2003 January 26-29 Washington. Available from: http://www.crtonline.org/body2.cfm?id=205&ArticleID=79 [accessed 28/01/2003]. 2003.
39. Maresta A, Varani E, Balducelli M, Aquilina M, Vecchi G. Abstract 2148: Sirolimus-eluting stent versus bare-metal stent in diabetic patients: results of the Italian multicenter, randomized "Dessert" study. Circulation 2007;116(2):465-6.
40. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, et al. Effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian multicenter randomized DESSERT study). American Journal of Cardiology 2008;101:1560-6.
41. Jimenez-Quevedo P, Hernando L, Gomez-Hospital JA, Iniguez A, Sanroman A, Alfonso F, et al. Five year follow-up of DIABETES trial: The final results. European Heart Journal 2011;32:354-5.
42. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, SanMartin M, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenosis: long-term results of the DIABETES trial. European Heart Journal 2007;28(16):1946-52.
43. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112(14):2175-83.
44. Díaz de la Llera LS, Ballesteros S, Nevado J, Fernández M, Villa M, Sánchez A, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. American Heart Journal 2007;154(1):164.e1-6.
45. Ischinger T. [European study of Axxion and Glycocalix long-term evaluation] German. Herz 2006;31:596.
46. Ischinger, T. Biosensors AXXION Glycocalix "Polymerless? PES: results from real world AXXION studies. TCT (Transcatheter Cardiovascular Therapeutics) 2007. Oct 21st 2007.
47. Ischinger, TA. EAGLE study: European study of Axxion and Glycocalix: long-term evaluation. Euro PCR 06. May 15th 2006.
48. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109(4):487-93.
49. Swanson N, Carver D, Kelly A, Gershlick A. Late stent thrombosis: long-term clinical results of the ELUTES polymer-free drug-eluting stent trial, BCIS (British Cardiovascular Intervention Society) Abstract 127. Heart 2007 2007;93(5):5-105.
50. Summary of safety and effectiveness data. http://www.accessdata.fda.gov/cdrh_docs/pdf6/P060033b.pdf [accessed March 2008].
51. Buellesfeld L, Grube E. ABT-578-eluting stents: the promising successor of sirolimus-and paclitaxel-eluting stent concepts?. Herz 2004;29(2):167-70.
52. Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, et al. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). Jacc: Cardiovascular Interventions 2009;2(12):1178.
53. Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114(8):798-806.
54. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Baldus S, et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. Eurointervention 2010;6(5):562-7.
55. Meredith I. Medtronic ENDEAVOR. CRF (Cardiovascular Research Foundation) drug-eluting stent symposium @ ACC 2004 Available from: http://www.tctmd.com/display/expert/pdf/105390/Meredith_Endeavor.pdf. [cited 2004 25/05/2004]. 2004.
56. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55.
57. Schofer J, Breithardt G, Wijns W, Gershlick AH, Rubino P, Simon R, et al. E-SIRIUS: 2-year clinical follow up in patients with de-novo lesions treated with sirolimus-eluting stents. European Cardiovascular Society Congress. Munich, 2004, issue 9390.
58. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362(9390):1093-9.
59. Abizaid A, Chaves AJ, Leon MB, Hauptmann K, Mehran R, Lansky AJ, et al. Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. Catheterization and Cardiovascular Interventions 2007;70:654-60.
60. Abizaid A, Chaves AJ, Leon MB, Hauptmann K, Mehran R, Lansky AJ, et al. Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. Catheterization and Cardiovascular Interventions 2007;70:654-60.
61. Rodriguez AE, Vigo CF, Delacasa A, Mieres J, Fernandez-Pereira C, Bernardi V, et al. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial. Catheterization & Cardiovascular Interventions 2011;77(3):335-342.
62. Rodriguez-Granillo AM, Mieres J, Femandez-Pereira C, Delacasa A, Vigo CF, Risau G, et al. Two-year reports of efficacy and safety end points from the randomised, multicentre and controlled EUCATAX trial. EuroIntervention 2011;7(Supplement M):M84.
63. Silber S, Gutierrez-Chico JL, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, et al. Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. Eurointervention 2011;7(1):64-73.
64. Brugaletta S, Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, et al. Impact of everolimus-eluting stents on stent thrombosis as compared to conventional bare metal stents in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial. European Heart Journal 2012;33:175. 2012;33:175.
65. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Rationale and design of the EXAMINATION trial: A randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention 2011;7(8):977-84.
66. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. The Lancet;380(9852):1482-90. 2012;380(9852):1482-90.
67. Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). American Journal of Cardiology 2005;95(1):113-6.
68. Grube E. Animal and first human results with the biosensors everolimus-eluting stent (FUTURE-I). TCT 2002 available from: http://www.tctmd.com/display/expert/pdf/53477/Grube-Everolimus.pdf (access 31/1/2003]. Washington DC, 2002.
69. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, et al. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71.
70. Grube E. FUTURE II: Multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. Transcatheter Cardiovascular Therapeutics (TCT) 2003. TCT 2003. TCTMD.com, 2003, issue 07/10/03.
71. Storger H, Grube E, Hofmann M, Schwartz F, Haase J. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. Journal of Interventional Cardiology 2004;17(6):387-90.
72. Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, et al. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. European Heart Journal 2010;31(16):2014-20.
73. http://clinicaltrials.gov/ct2/show/NCT00220558. GISSOC II: sirolimus eluting stent versus bare metal stent in chronic total coronary occlusions. http://clinicaltrials.gov/ct2/show/NCT00220558 [accessed March 2008].
74. Sánchez PL, Gimeno F, Ancillo P, Sanz JJ, Alonso-Briales JH, Bosa F, et al. Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circulation. Cardiovascular interventions 2010;3(4):297-307.
75. Tierala I, Syvanne M, Kupari M. Randomised comparison of a paclitaxel-eluting and a bare metal stent in STEMI-PCI. American Journal of Cardiology -TCT abstracts. 2006:78M.
76. Han SH, Ahn TH, Kang WC, Oh KJ, Chung WJ, Shin MS, et al. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study. American Heart Journal 2006;152(5):887.e1-887.e7.
77. Han YL, Wang SL, Jing QM, Yu HB, Wang B, Ma YY, et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chinese Medical Journal 2007;120(7):552-6.
78. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Chiu Wong S, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. New England Journal of Medicine May 2007;360:1946-59.
79. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. New England Journal of Medicine 2009;360(19):1946-59.
80. Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. Journal of the American College of Cardiology 2010;56(19):1597-604.
81. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377(9784):2193-204.
82. Ribeiro HB, Campos CA, Lopes AC, Esper RB, Abizaid A, Meireles GX, et al. Randomised comparison of the efficacy and safety of a novel DES with biodegradable polymer and cobalt-chromium alloy -INSPIRON I trial. EuroIntervention 2011;7(Supplement M):M98.
83. Jin HG, Liu ZJ, Yang W, Wang WQ, Shi J, Wang DY, et al. Comparison of effects between China made sirolimus-eluting stents and bare stents for treating patients with acute myocardial infarction. Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2007;35(8):697-700.
84. Morice M, Bestehorne H, Carrie D, Macaya C, Aengevaeren W, Wijns W, et al. Direct stenting of de novo coronary stenosis with tacrolimus-eluting versus carbon-coated carbostents. the randomized JUPITER II trial. EuroIntervention 2006;2:45-52.
85. König A, Leibig M, Rieber J, Schiele TM, Theisen K, Siebert U, et al. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. American Heart Journal 2007;153(6):979.e1-8.
86. Li S, Fu X, Liu J, Wu W, Gu X, Ma N, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary small vessel lesions. American Journal of Cardiology 2004;94(6A):218E-218E.
87. Atary JZ, van der Hoeven BL, Liem SS, Jukema JW, van der Bom JG, Atsma DE, et al. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). American Journal of Cardiology 2010;106(1):4-12.
88. Boden H, Van Der Hoeven BL, Atary JZ, Liem SS, Van Der Wall EE, Schalij MJ. 5-year outcomes of the MISSION intervention study; A randomized comparison of sirolimus-eluting to bare-metal stent implantation in patients with STEMI. European Heart Journal 2011;32:654.
89. Boden H, van der Hoeven BL, Liem SS, Atary JZ, Cannegieter SC, Atsma DE, et al. Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. Eurointervention 2012;7(9):1021-9.
90. van der Hoeven BL, Liem S, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! intervention study. Journal of the American College of Cardiology 2008;51(6):618-26.
91. Guagliumi G, Sirbu V, Bezerra H, Biondi-Zoccai G, Fiocca L, Musumeci G, et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. Jacc: Cardiovascular Interventions 2010;3(6):680-7.
92. Poerner TC, Otto S, Janiak F, Gassdorf J, Figulla HR. A prospective randomized study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6 months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (octopus trial). Journal of the American College of Cardiology 2012;1:E281.
93. Poerner TC, Otto S, Janiak F, Gassdorf J, Nitsche K, Jung C, et al. A prospective randomized trial using optical coherence tomography to compare the Xience V everolimus-eluting stent with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial). European Heart Journal 2012;33:520.
94. Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Granillo AM, et al. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. Eurointervention 2009;5(2):255-64.
95. Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, et al. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: Three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial. Catheterization and Cardiovascular Interventions 2012;80(3):385-94.
96. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheterization and Cardiovascular Interventions 2007;69(6):790-8.
97. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. European Heart Journal 2005;26(13):1262-8.
98. Lemos PA. Randomised evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results. Catheterization and Cardiovascular Interventions 2009; Vol. 74, issue 5:665-73.
99. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. Eurointervention 2012;8(1):117-9.
100. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, et al. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheterization & Cardiovascular Interventions 2009;74(5):665-73.
101. Lemos PA, Moulin B, Perin MA, Oliveira LARR, Arruda JA, Lima VC, et al. Rationale and design for the PAINT randomized trial [Fundamento e desenho do teste randomizado PAINT]. Arquivos Brasileiros de Cardiologia 2009;93(6):547-53.
102. Lemos PA. Randomised evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results. Catheterization and Cardiovascular Interventions 2009; Vol. 74, issue 5:665-73.
103. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. Eurointervention 2012;8(1):117-9.
104. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, et al. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheterization & Cardiovascular Interventions 2009;74(5):665-73.
105. Lemos PA, Moulin B, Perin MA, Oliveira LARR, Arruda JA, Lima VC, et al. Rationale and design for the PAINT randomized trial [Fundamento e desenho do teste randomizado PAINT]. Arquivos Brasileiros de Cardiologia 2009;93(6):547-53.
106. Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. Jacc: Cardiovascular Interventions 2009;2(6):515-23.
107. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. American Heart Journal 2009;158(4):e43-50.
108. Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. Jacc: Cardiovascular Interventions 2009;2(6):515-23.
109. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. American Heart Journal 2009;158(4):e43-50.
110. Dirksen M, Vink M, Suttorp M, Tijssen J, Patterson M, Slagboom T, et al. Two year follow up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. EuroIntervention 2009;4:64-70.
111. Laarman GJ, Suttorp MJ, Dirksen MT, Van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. New England Journal of Medicine 2006;355:1105-13.
112. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. Jacc: Cardiovascular Interventions 2011;4(1):24-9.
113. Heldman A, Farhat N, Fry E, Cummins F, Roubin G, McGarvey J, et al. Paclitaxil-eluting stents for cytostatic prevention of restenosis: patency study follow-up. American Journal of Cardiology -TCT abstracts available from: http://www.tctmd.com/display/expert/pdf/47017/Heldman-PATENCY.pdf [accessed 7/1/2003]. 2002; Vol. 1, issue 6 (S1):H1-H4.
114. Pilgrim T, Raber L, Limacher A, Loffel L, Wenaweser P, Cook S, et al. Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. Jacc: Cardiovascular Interventions 2011;4(6):672-82.
115. Rahel BM, Laarman GJ, Kelder JC, ten Berg Jur M, Suttorp MJ. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries. A randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). American Heart Journal 2009;157:149-55.
116. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MAR, Kiemeneij F, et al. Primary stenting of totally occluded native coronary arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;114(9):921-8.
117. Van den Branden BJ, Rahel BM, Laarman GJ, Slagboom T, Kelder JC, Ten Berg JM, et al. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). Eurointervention 2012;7(10):1189-96.
118. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents -Three-year results of the RAVEL trial. Circulation 2005;111(8):1040-4.
119. Fajadet J, Perin M, Hayashi EB, Colombo A, Schuler G, Barragan P, et al. 210-Day follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx VELOCITY(TM) balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. Journal of the American College of Cardiology 2002;39(Supp 1):20.
120. Morice M-C. Sirolimus-eluting stents for coronary revascularization. Cardiology Review 2003;20(5):36-9.
121. Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents. Five-year results of the RAVEL Trial. Journal of the American College of Cardiology 2007;50(14):1299-304.
122. Morice MC, Serruys PW, Sousa JE. Erratum: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New England Journal of Medicine 2002;346(23):1173-80.
123. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New England Journal of Medicine 2002;346(23):1773-80.
124. Kelbæk H, Kløvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrøm T. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions. 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. Journal of the American College of Cardiology 2008;51:2011-6.
125. Kelbæk H, Thuesen L, Helqvist S, Kløvgaard L, Jørgensen E, Aljabbari S, et al. The Stenting Coronary Arteries in Non-stress/benestent disease (SCANDSTENT) trial. Journal of the American College of Cardiology 2006;47(2):449-55.
126. Grube E, Lansky A, Hauptman K, Di Mario C, Di Sciascio G, Columbo A, et al. High dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. Journal of the American College of Cardiology 2004;44:1368-72.
127. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, et al. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002;106(14):1788-93. [MEDLINE: 15]
128. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, et al. One-year results of the SCORPIUS study. A German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Journal of the American College of Cardiology 2007;50(17):1627-34.
129. Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F, et al. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. American Heart Journal 2012;163(3):446-53.
130. Chechi T, Vittori G, Biondi Zoccai GGL, Vecchio S, Falchetti E, Spaziani G. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). Journal of Interventional Cardiology 2007;20(4):282-91.
131. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, et al. Randomized trial of Sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). Journal of the American College of Cardiology 2007;49(19):1924-30.
132. Musto C, Fiorilli R, De Felice F, Patti G, Nazzaro M, Scappaticci M, et al. Long-term outcome of sirolimus-eluting versus bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial. Giornale Italiano di Cardiologia 2011;12(supplement 1):4S.
133. Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. Journal of the American College of Cardiology 2010;55(8):810-4.
134. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries -a randomized trial. JAMA 2004;292(22):2727-34.
135. Menozzi A, Solinas E, Ortolani P, Repetto A, Saia F, Piovaccari G, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. European Heart Journal 2009;30(17):2095-101.
136. Chacko R, Mulhearn M, Novack V, Novack L, Mauri L, Cohen SA, et al. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. Jacc: Cardiovascular Interventions 2009;2(6):498-503.
137. Holmes DR, Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109(5):634-40.
138. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New England Journal of Medicine 2003;349(14):1315-23.
139. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SiRolImUS-coated Bx velocity balloon-expandable stent in the treatmeNt of patients with de novo coronary artery lesions) substudy. Circulation 2004;109(19):2273-8.
140. Weisz G, Leon MB, Holmes DR, Kereiakes DJ, Popma JJ, Teirstein PS, et al. Five-year follow-up after sirolimus-eluting stent implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. Journal of the American College of Cardiology 2009;53(17):1488-97.
141. Weisz G, Leon MB, Holmes Jr. DR, Kereiakes DJ, Clark MR, Cohen BM, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. Journal of the American College of Cardiology 2006;47(7):1350-5.
142. Grube E. SPIRIT FIRST. CRT 2005 Available from:http://www.crtonline.org/Topics.aspx?CAT=155 [accessed March 2008]. 2005.
143. Piek, JJ. SPIRIT FIRST Two-year follow up results. EuroPCR06 conference. 2006.
144. Serruys PW, Ong ATL, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent:the SPIRIT first trial. EuroPCR online.com available at http://www.europcronline.com/eurointervention/1st_issue/07/index.php?ind=1(March 2008] 2005;1:58-65.
145. Stone GW. EuroPCR 2007 http://www.europcronline.com/fo/lecture/view_slide.php?idCongres=3&id=3742 [Accessed April 2008]. 2007.
146. Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, et al. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheterization & Cardiovascular Interventions 2010;75(7):997-1003.
147. Costa R, Mueller R, Abizaid A, Hauptmann KE, Grube E. STEALTH I: 5-year follow-up from a prospective randomized study of Biolimus A9-eluting stent with a biodegradable polymer coating vs a bare metal stent. Journal of the American College of Cardiology 2011;1:B58.
148. Grube E, Abizaid A, Hauptman K. Safety and performance evaluation of the biosensors international's Biolimu A9 drug eluting stent (Biomatrix): STEALTH 1: a 4-year safety follow-up. 2008. http://www.biosensors.com/intl/sites/default/files/pdfs/clinical_program/stealth_1_4_year_data.pdf (accessed June 2013 2013).
149. Grube E, Hauptman K, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention 2005;1(1):53-7.
150. Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 2009;54(20):1900-1.
151. Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. Journal of the American College of Cardiology 2007;50(2):138-45.
152. Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, et al. High-dose BoluS TiRofibAn and sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study -Protocol design and demography of the first 100 patients. Cardiovascular Drugs & Therapy 2004;18(3):225-30.
153. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293(17):2109-17.
154. Strozzi M, Anic D. Comparison of stent graft, sirolimus stent, and bare metal stent implanted in patients with acute coronary syndrome: clinical and angiographic follow up. Croatian Medical Journal 2007;48(3):348-52.
155. Boston Scientific. Clinical Trial and Registry Summary. http://www.bostonscientific.com/templatedata/imports/collateral/AboutBSC/bsc_taxusI_ctsummary_030206.pdf [accessed March 2008].
156. Grube E. TAXUS I two year results -sustained benefit over time. EuroPCR, Paris, 21 May 2003.
157. Grube E, Silber S, Hauptmann KE, Buellesfeld L, Mueller R, Lim V, et al. Two-year-plus follow up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). The American Journal of Cardiology 2005;96(1):79.
158. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;106:76-80.
159. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107(1):38-42.
160. Müller R, Gerckens U, Hauptmann KE, Silber S. The TAXUS I study with the Paclitaxel-coated NIRx stent -angiographical results and clinical follow up. Jahrestagung der Deutschen Gesellschaft für Kardiologie 2002;91(Suppl 1):I/65. [MEDLINE: 27]
161. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108 (7):788-94.
162. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009;120(15):1498-504.
163. Silber S, Colombo A, Banning AP, Hauptmann KE, Drzewiecki J, Koglin J, et al. Abstract 2152: long-term safety and clinical efficacy in the slow-and moderate-release polymer-based, paclitaxel-eluting TAXUS stent: final 5-year results of the TAXUS II trial. Circulation 2007;116(2):466-7.
164. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108 (7):788-94.
165. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009;120(15):1498-504.
166. Silber S, Colombo A, Banning AP, Hauptmann KE, Drzewiecki J, Koglin J, et al. Abstract 2152: long-term safety and clinical efficacy in the slow-and moderate-release polymer-based, paclitaxel-eluting TAXUS stent: final 5-year results of the TAXUS II trial. Circulation. 2007; Vol. 116, issue 2:466-7.
167. Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). Jacc: Cardiovascular Interventions 2009;2(12):1248-59.
168. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine 2004;350(3):221-31.
169. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109(16):1942-7.
170. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy CD, Mann T, et al. Safety and durable efficacy of the polymer-based, paclitaxel-eluting TAXUS stent: final 5-year outcomes from the TAXUS IV trial TCT65. The American Journal of Cardiology. 2007; Vol. 100, issue 8 (Supplement 1):S33-8.
171. Ellis SG, Cannon LA, Mann T, Greenberg JD, Cambier PA, O'Shaughnessy CD, et al. Three-year clinical results from the TAXUS V de novo trial: long-term safety and efficacy of the paclitaxel-eluting TAXUS stent in complex lesions TCT 64. The American Journal of Cardiology 2007;100 (8 Supplement 1):S33-8.
172. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based Paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294(10):1215-23.
173. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112(21):3306-13.
174. Grube E. TAXUS VI. A randomised trial of moderate release polymer-based paclitaxel-eluting TAXUS stent for the treatment of longer lesions. 9 Month clinical results. Euro PCR 2004. 2004.
175. Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo AT, et al. TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 2009;4:572-7.
176. Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. TAXUS VI 2-year follow up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. European Heart Journal 2007;28(21):2578-82.
177. Hess OM, Karjalainen P. Drug-eluting or titanium-coated stents in acute myocardial infarction: An issue of safety. EuroIntervention 2010;6:Supp H.
178. Karjalainen P. A 3-year follow up report from the TITAX AMI trial. EuroIntervention 2010; Vol. 6.
179. Karjalainen PP, Ylitalo A, Niemela M, Kervinen K, Makikallio T, Pietila M, et al. Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. Annals of Medicine 2009;41(8):599-607.
180. Tuomainen PO, Ylitalo A, Niemela M, Pietila M, Sia J, Nyman K, et al. Long-term outcome after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction: A five-year follow-up of the TITAX-AMI trial. Journal of the American College of Cardiology 2011;1:B89.
181. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. New England Journal of Medicine 2006;355(11):1093-104.
182. Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). Jacc: Cardiovascular Interventions 2011;4(1):14-23.
183. Wang B, Han YL, Jing QM, Wang SL, Ma YY, Wang G, et al. Therapeutic effect and safety of drug eluting stent for patients with acute ST-elevation anterior wall myocardial infarction by left anterior descending artery occluded abruptly. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2010;90(30):2099-102.
184. Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for the treatment of unprotected left main coronary artery stenosis. Journal of the American College of Cardiology 2007;50(6):491-7.
185. Gao H, Yan HB, Zhu XL, Li N, Ai H, Wang J, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. Chinese Medical Journal 2007;120(10):863-7.
186. Gioia G, Matthai W, Benassi A, Rana H, Levite HA, Ewing LG. Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction. Catheterization & Cardiovascular Interventions 2006;68:392-8.
187. Halkin A, Selzer F, Marroquin O, Laskey W, Detre K, Cohen H. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. Journal of Invasive Cardiology 2006;18:577-83.
188. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. European Heart Journal 2005;26:1475-81.
189. Hoffmann R, Stellbrink E, Schroder J, Grawe A, Vogel G, Blindt R, et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. American Journal of Cardiology 2007;100:1347-52.
190. Kim Y-H, Park S-W, Lee CW, Hong M-K, Gwon H-C, Jang Y, et al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheterization & Cardiovascular Interventions 2006;67:181-7.
191. Lasave LI, Costa JdR, Jr, Abizaid AA, Feres F, Tanajura LF, Staico R, et al. A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx) and the non-drug-eluting TriMaxx stent. Journal of Invasive Cardiology 2007;19:303-8.
192. Li AH, Liau CS, Chuang WP, Yeih DF, Chu SH. Phosphorylcholine-coated dexamethasone eluting stent in the prevention of restenosis: a randomized trial in a single hospital. Acta Cardiologica Sinica 2007;23(1):35-42.
193. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ, et al. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. American Journal of Cardiology 2007;100:56M-61M.
194. Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. American Heart Journal 2006;152:1168-74.
195. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization -The TiNOX trial. Circulation 2005;111:2617-22.
196. Pittl U, Brunner-La Rocca H, Kaiser C, Bonetti PO, Hunziker P, Linka A, et al. http://circ.ahajournals.org.ezproxy.liv.ac.uk/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_739?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=stents&searchid=1&FIRSTINDEX=40&volume=114&issue=18+Supplement&resourcetype=HWCIT [accessed March 2009]. 2006.
197. Lopez-Minguez JR, Nogales Asensio Jm, Doncel Vecino LJ, Gonzalez Fernandez Mr, Merchan Herrera A, Martinez Caceres G, et al. Initial clinical and angiographic results of the Titanic XV prospective randomised trial: The Titan vs. Everolimus (Xience-V) stent in diabetic patients. EuroIntervention 2011 2011;7:M79.
198. Lopez-Minguez JR, Nogales-Asensio JM, Doncel Vecino LJ, Gonzalez Fernandez MR, Domingo FP, Romero PM, et al. Clinical and angiographic results of the titanium vs everolimus stent in diabetic patients randomized trial (TITANIC-XV). Journal of the American College of Cardiology 2011;1:B114-B115.
199. Nogales JM, Lopez Minguez JR, Doncel Vecino LJ, Gonzalez Fernandez MR, Merchan Herrera A, Martinez Caceres G, et al. Initial angiographic results of the TITANIC-XV prospective randomized trial: the titan vs everolimus stent in diabetic patients. European Heart Journal 2011;32(1043):1035.
200. Nogales JM, Lopez-Minguez JR, Doncel Vecino LJ, Pomar Domingo F, Martinez Romero P, Fernandez Diaz JA, et al. Initial clinical results of the TITANIC-XV prospective randomized trial: The titan vs everolimus stent in diabetic patients. European Heart Journal 2011;32:744.
201. Van Langenhove G, Verheye S, Vermeersch P, Benit E, Vrolix M. Comparison of a bare metal stent with a Bioabsorbable oil based Corolimus -Coated stent for the treatment of coronary artery lesions: Results of a single-blind randomized controlled first in man trial [Koroner arter lezyonlarinin tedavisinde ciplak metal stent ile biyolojik yolla emilebilen Corolimus kapli stentlerin karsilastirmasi: Insanlarda yapilan ilk cift-kor randomize kontrollu calismanin sonuclari.]. Turk Kardiyoloji Dernegi Arsivi 2011 2011;39:102.
202. Costa JDR, Abizaid A, Costa R, Almeida B, Feres F, Perin M, et al. Very long-term results of a the VestaSync 2 trial with the novel polymer-free hydroxyapatite sirolimus-eluting stent. EuroIntervention 2012;8:N85.
203. Costa JR, Abizaid A, Feres F, Oliveira B, Perim M, Costa R, et al. Preliminary results of the multicentric, double-blinded, randomised, Vestasync II trial. EuroIntervention 2011;7:M99.
204. De Ribamar Costa J, Abizaid A, Costa R, Almeida B, Feres F, Perin M, et al. Two-year sustained efficacy of a novel, polymer-free sirolimus eluting stent: Late results of the Vestasync ii trial. Journal of the American College of Cardiology 2012;1:E212.
205. De Ribamar Costa J, Costa R, Almeida B, Perim M, Feres F, De Brito FS, et al. One-year results of the multicentric, double-blinded, randomized, VESTAsync II trial. Journal of the American College of Cardiology 2011;1):B62 2011;1:B62.
206. Jeger R, Pfisterer M, Alber H, Eberli F, Galatius S, Naber C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitats Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. American Heart Journal 2012;163(2):136-41.e1.
207. Pitt J, Reeve M, Whitlam H, Pulikal G, Ment N, El Gaylani N, et al. Drug eluting versus bare metal stents in acute ST elevation myocardial infarction (DEVINE) -a randomised control trial. European Heart Journal 2007;28 (Abstract Supplement):206.
208. Pasceri V, Granatelli A, Pristipino C, Pelliccia F, Speciale G, Pironi B, et al. Intervention in acute myocardial infarction. American Journal of Cardiology -TCT abstracts 2003;TCT-1:1L.
209. King III SB, Smith Jr. SC, Hirshfeld Jr. JW, Jacobs AK, Morrison DA, Williams DO. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 2008;117:261-95.
210. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
211. Cutlip DE, Windecker S, Roxana Mehran R, Boam A, Cohen DJ, van Es GA, S, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
212. British Cardiovascular Intervention Society. National Audit of Percutaneous Coronary Interventional Procedures. http://www.hqip.org.uk/assets/NCAPOP-Library/NCAPOP-2012-13/PCIPNational-Audit-Report-NICOR-2012.pdf [accessed August 2013].
213. British Heart Foundation. European Cardiovascular Disease Statistics 2008. http://www.heartstats.org/datapage.asp?id=7998 [accessed March 2008].
214. Bischof M, Briel M, Bucher HC, Nordmann A. Cost-effectiveness of drug-eluting stents in a US Medicare setting: a cost-utility analysis with 3-year clinical follow-up data. Value In Health 2009;12:649-56.
215. Cook S, Walker A, Hügli O, Togni M, Meier B. Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clinical Research in Cardiology 2007;96(6):375-82.
216. Cutlip DE, Chauhan MS, Baim DS, Ho KKL, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. Journal of the American College of Cardiology 2002;40(12):2082-9.
217. Cutlip DE, Windecker S, Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115(17):2344-51.
218. De Luca, G.Dirksen, M. T.Spaulding, C.Kelbaek, H.Schalij, M.Thuesen, L, et al. Drug-eluting vs bare-metal stents in primary angioplasty: A pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine 2012;172(8):611-621.
219. Dundar Y, Dickson R, Haycox A, Walley T. Comparison of conference presentations and abstracts with published full-text articles in health technology assessment of rapidly evolving technologies. The 1st Annual Meeting of Health Technology Assessment International. Krakow, Poland, 2004 May 30-June 2:303.
220. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. European Heart Journal 2005;26:804-47.
221. Food, Drug Administration. FDA Statement on Coronary Drug-Eluting Stents (September 14, 2006). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=61.
222. Gunn J, Crossman D, Grech ED, Cumberland D. New developments in percutaneous coronary intervention. BMJ 2003;327(7407):150-3.
223. Brunner E, Burke M, Cleland J, Conti A, Dans A, Ebrahim S (Coordinating Editor), et al. The Cochrane Heart Group. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2004, issue 4.
224. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane-handbook.org. updated March 2011.
225. Hill RA, Boland A, Dickson R, Dundar Y, Haycox A, McLeod C, et al. Drug-eluting stents: a systematic review and economic evaluation. HTA 2007; Vol. 11, issue 46.
226. King SB, Smith SC, Hirshfield JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Journal of the American College of Cardiology 2008;51(2):172-209.
227. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
228. Lenzer J. Longer, better studies are needed to assess safety of coronary stents, FDA tells industry. BMJ 2008; Vol. 336:743.
229. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technology Assessment (Winchester, England) 2000;4(23):1-153.
230. Miller, R. Many patients getting DES would do as well with bare-metal stents: NCDR registry. Theheart.org[Clinical Conditions > Interventional/Surgery > Interventional/Surgery] Jul 10, 2012. Accessed at http://www.theheart.org/article/1423473.do on Aug 5, 2013.
231. National Institute for Clinical Excellence. Drug-eluting stents for the treatment of coronary artery disease. Technology Appraisal Guidance. Vol. 152, London: National Institute for Clinical Excellence, 2008. [1-84257-413-2]
232. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
233. Serruys PW, Gershlick AH. Handbook of drug eluting stents. London: Taylor & Francis, 2005.
234. Silber S, Albertsson P. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. European Heart Journal 2005;26(8):804-47.
235. Villanueva EV, Wasiak J, Petherick ES. Percutaneous transluminal rotational atherectomy for coronary artery disease (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003334]
236. World Health Organization. The top 10 causes of death Fact sheet No. 310. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
237. Hill RA, Bagust A, Bakhai A, Dickson R, Dundar Y, Haycox A, et al. Coronary artery stents and appraisal of drug-eluting stents: a rapid and systematic review. Health Technology Assessment 2004; Vol. 8.